Download PDF
Clin Colon Rectal Surg 2018; 31(03): 199-204
DOI: 10.1055/s-0037-1602240
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Development of Preclinical Models to Understand and Treat Colorectal Cancer

Judith S. Sebolt-Leopold
1   Department of Radiology, University of Michigan Medical School, Ann Arbor, Michigan
2   Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
01 April 2018 (online)

    Permissions and Reprints

Abstract

The establishment and validation of preclinical models that faithfully recapitulate the pathogenesis and treatment response of human colorectal cancer (CRC) is critical to expedient therapeutic advances in the clinical management of this disease. Integral to the application of precision medicine for patients diagnosed with metastatic CRC is the need to understand the molecular determinants of response for a given therapy. Preclinical models of CRC have proven invaluable in answering many of our basic questions relating to the molecular aberrations that drive colorectal tumor progression. This review will address the comparative merits and limitations of the broad spectrum of in vitro and in vivo models available for study of colorectal tumors and their response to experimental therapies.

Keywords

organoid - xenograft - genetically engineered mouse model
 

  • References

  • 1 Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A 2012; 109 (51) 21046-21051
    CrossrefPubMedGoogle Scholar
  • 2 Barretina J, Caponigro G, Stransky N. , et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483 (7391): 603-607
    CrossrefPubMedGoogle Scholar
  • 3 Lind GE, Danielsen SA, Ahlquist T. , et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011; 10: 85
    CrossrefPubMedGoogle Scholar
  • 4 Sur S, Pagliarini R, Bunz F. , et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009; 106 (10) 3964-3969
    CrossrefPubMedGoogle Scholar
  • 5 Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001; 19 (10) 940-945
    CrossrefPubMedGoogle Scholar
  • 6 Mouradov D, Sloggett C, Jorissen RN. , et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 2014; 74 (12) 3238-3247
    CrossrefPubMedGoogle Scholar
  • 7 Medico E, Russo M, Picco G. , et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 2015; 6: 7002
    CrossrefPubMedGoogle Scholar
  • 8 Hoffmann OI, Ilmberger C, Magosch S, Joka M, Jauch KW, Mayer B. Impact of the spheroid model complexity on drug response. J Biotechnol 2015; 205: 14-23
    CrossrefPubMedGoogle Scholar
  • 9 Lee SH, Hong JH, Park HK. , et al. Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors. Cancer Lett 2015; 367 (01) 34-42
    CrossrefPubMedGoogle Scholar
  • 10 van de Wetering M, Francies HE, Francis JM. , et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015; 161 (04) 933-945
    CrossrefPubMedGoogle Scholar
  • 11 Weeber F, van de Wetering M, Hoogstraat M. , et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A 2015; 112 (43) 13308-13311
    CrossrefPubMedGoogle Scholar
  • 12 Heyer J, Yang K, Lipkin M, Edelmann W, Kucherlapati R. Mouse models for colorectal cancer. Oncogene 1999; 18 (38) 5325-5333
    CrossrefPubMedGoogle Scholar
  • 13 Karim BO, Huso DL. Mouse models for colorectal cancer. Am J Cancer Res 2013; 3 (03) 240-250
    PubMedGoogle Scholar
  • 14 Taketo MM, Edelmann W. Mouse models of colon cancer. Gastroenterology 2009; 136 (03) 780-798
    CrossrefPubMedGoogle Scholar
  • 15 Johnson RL, Fleet JC. Animal models of colorectal cancer. Cancer Metastasis Rev 2013; 32 (1-2): 39-61
    CrossrefPubMedGoogle Scholar
  • 16 McIntyre RE, Buczacki SJ, Arends MJ, Adams DJ. Mouse models of colorectal cancer as preclinical models. BioEssays 2015; 37 (08) 909-920
    CrossrefPubMedGoogle Scholar
  • 17 Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5 (09) 741-754
    CrossrefPubMedGoogle Scholar
  • 18 Forbes SA, Beare D, Gunasekaran P. , et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43 (Database issue): D805-D811
    CrossrefPubMedGoogle Scholar
  • 19 Garnett MJ, Edelman EJ, Heidorn SJ. , et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483 (7391): 570-575
    CrossrefPubMedGoogle Scholar
  • 20 Klijn C, Durinck S, Stawiski EW. , et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol 2015; 33 (03) 306-312
    CrossrefPubMedGoogle Scholar
  • 21 Johnson JI, Decker S, Zaharevitz D. , et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84 (10) 1424-1431
    CrossrefPubMedGoogle Scholar
  • 22 Sarraf P, Mueller E, Jones D. , et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4 (09) 1046-1052
    CrossrefPubMedGoogle Scholar
  • 23 Kulke MH, Demetri GD, Sharpless NE. , et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8 (05) 395-399
    CrossrefPubMedGoogle Scholar
  • 24 Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006; 66 (07) 3351-3354 , discussion 3354
    CrossrefPubMedGoogle Scholar
  • 25 Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A 1991; 88 (20) 9345-9349
    CrossrefPubMedGoogle Scholar
  • 26 Rashidi B, Gamagami R, Sasson A. , et al. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res 2000; 6 (06) 2556-2561
    PubMedGoogle Scholar
  • 27 Dangles-Marie V, Pocard M, Richon S. , et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007; 67 (01) 398-407
    CrossrefPubMedGoogle Scholar
  • 28 Julien S, Merino-Trigo A, Lacroix L. , et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012; 18 (19) 5314-5328
    CrossrefPubMedGoogle Scholar
  • 29 Ziemke EK, Dosch JS, Maust JD. , et al. Sensitivity of KRAS-mutant colorectal cancers to combination therapy that cotargets MEK and CDK4/6. Clin Cancer Res 2016; 22 (02) 405-414
    CrossrefPubMedGoogle Scholar
  • 30 Bertotti A, Migliardi G, Galimi F. , et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1 (06) 508-523
    CrossrefPubMedGoogle Scholar
  • 31 Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998; 25 (05) (Suppl. 11) 39-46
    PubMedGoogle Scholar
  • 32 Migliardi G, Sassi F, Torti D. , et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012; 18 (09) 2515-2525
    CrossrefPubMedGoogle Scholar
  • 33 Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015; 15 (05) 311-316
    CrossrefPubMedGoogle Scholar
  • 34 Hidalgo M, Amant F, Biankin AV. , et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014; 4 (09) 998-1013
    CrossrefPubMedGoogle Scholar
  • 35 Di Nicolantonio F, Bardelli A. Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?. Clin Cancer Res 2013; 19 (11) 2794-2796
    CrossrefPubMedGoogle Scholar
  • 36 Roper J, Hung KE. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol Sci 2012; 33 (08) 449-455
    CrossrefPubMedGoogle Scholar
  • 37 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61 (05) 759-767
    CrossrefPubMedGoogle Scholar
  • 38 Smith G, Carey FA, Beattie J. , et al. Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002; 99 (14) 9433-9438
    CrossrefPubMedGoogle Scholar
  • 39 Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487 (7407): 330-337
    CrossrefPubMedGoogle Scholar
  • 40 Hinoi T, Akyol A, Theisen BK. , et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67 (20) 9721-9730
    CrossrefPubMedGoogle Scholar
  • 41 Hung KE, Maricevich MA, Richard LG. , et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 2010; 107 (04) 1565-1570
    CrossrefPubMedGoogle Scholar
  • 42 Martin ES, Belmont PJ, Sinnamon MJ. , et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res 2013; 19 (11) 2929-2940
    CrossrefPubMedGoogle Scholar
  • 43 Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74 (06) 957-967
    CrossrefPubMedGoogle Scholar